Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) FCF Margin (2016 - 2025)

Voyager Therapeutics' FCF Margin history spans 11 years, with the latest figure at 187.27% for Q4 2025.

  • For Q4 2025, FCF Margin rose 4662.0% year-over-year to 187.27%; the TTM value through Dec 2025 reached 329.16%, down 29390.0%, while the annual FY2025 figure was 329.16%, 30562.0% down from the prior year.
  • FCF Margin for Q4 2025 was 187.27% at Voyager Therapeutics, up from 234.33% in the prior quarter.
  • Across five years, FCF Margin topped out at 5197.26% in Q1 2022 and bottomed at 2580.06% in Q2 2022.
  • The 5-year median for FCF Margin is 210.58% (2024), against an average of 168.22%.
  • The largest annual shift saw FCF Margin soared 553058bps in 2022 before it crashed -511549bps in 2023.
  • A 5-year view of FCF Margin shows it stood at 34.23% in 2021, then surged by 1917bps to 690.32% in 2022, then plummeted by -104bps to 27.22% in 2023, then plummeted by -759bps to 233.9% in 2024, then increased by 20bps to 187.27% in 2025.
  • Per Business Quant, the three most recent readings for VYGR's FCF Margin are 187.27% (Q4 2025), 234.33% (Q3 2025), and 660.88% (Q2 2025).